CompanyGraph
Shenzhen Salubris Pharmaceuticals Co. Ltd.
002294 · SZSE · China
salubris.comFinancials as of FY2024 · latest on file
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $5.75B, above the global median of $1.15B
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.60%Below 5Y avg (2.51%)
Annual Rate
CNY 0.55Paid annual
Payout Ratio
83.3%Moderate
Payback Period
59.4 yr
Last Ex-Dividend
May 26, 2026
The reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
38.77BCNY5.75B · vs all stocks (USD)
Trailing P/E
57.97xRevenue (TTM)
4.52BCNY670.15M · vs all stocks (USD)
Profit Margin
14.97%Beta
-0.2470xvs all stocks
52-Week Change
-31.75%vs all stocks
Market Capitalization
38.77BCNY5.75B · vs all stocks (USD)
Enterprise Value
37.69BCNY5.59B · vs all stocks (USD)
Trailing P/E
57.97xForward P/E
54.34xPrice to Sales (TTM)
8.58xPrice to Book (MRQ)
4.24xEnterprise to Revenue
8.34xEnterprise to EBITDA
35.37xGross Margin
75.31%Profit Margin
14.97%Operating Margin
20.06%Return on Assets (TTM)
3.80%Return on Equity (TTM)
7.41%Revenue (TTM)
4.52BCNY670.15M · vs all stocks (USD)
Revenue per Share (TTM)
4.01CNYUpdated Aug 19, 2026Quarterly Revenue Growth
15.70%Gross Profit (TTM)
3.39BCNY502.48M · vs all stocks (USD)
EBITDA (TTM)
855.39MCNY126.85M · vs all stocks (USD)
Net Income (TTM)
676.45MCNY100.32M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
12.50%Operating Cash Flow (TTM)
1.07BCNY158.43M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
77.72MCNY11.53M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.5500CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
1.60%vs all stocks
5-Year Average Dividend Yield
2.51%vs all stocks
Payout Ratio
83.33%Minority Interest (Equity)
40.17MCNYFY2024 · Dec 31, 2024Revenue
4.01BCNYFY2024 · Dec 31, 2024Cost of Goods Sold
1.10BCNYFY2024 · Dec 31, 2024Gross Profit
2.91BCNYFY2024 · Dec 31, 2024Operating Income
771.19MCNY114.37M · vs all stocks (USD)
Pre-tax Income
632.52MCNYFY2024 · Dec 31, 2024Income Tax Expense
27.36MCNYFY2024 · Dec 31, 2024Net Income
605.16MCNYFY2024 · Dec 31, 2024EBIT
648.69MCNYFY2024 · Dec 31, 2024EBITDA (Income Statement)
1.21BCNYFY2024 · Dec 31, 2024Research & Development
421.24MCNYFY2024 · Dec 31, 2024Selling, General & Administrative
1.06BCNYFY2024 · Dec 31, 2024Other Operating Expenses
50.87MCNYFY2024 · Dec 31, 2024Non-operating Interest Income
47.06MCNYFY2024 · Dec 31, 2024Non-operating Interest Expense
16.17MCNYFY2024 · Dec 31, 2024EPS (Basic)
0.5400CNYFY2024 · Dec 31, 2024EPS (Diluted)
0.5400CNYFY2024 · Dec 31, 2024Basic Shares Outstanding
1.11BSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
1.11BSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
605.16MCNYFY2024 · Dec 31, 2024Minority Interests (P&L)
-3.59MCNYFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00CNYFY2024 · Dec 31, 2024Operating Cash Flow
449.94MCNYFY2024 · Dec 31, 2024Free Cash Flow
-174.23MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
1.10BCNYFY2024 · Dec 31, 2024Starting Profit (CF Statement)
605.16MCNYFY2024 · Dec 31, 2024Other Non-cash Items
14.66MCNYFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-57.58MCNYFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
-112.31MCNYFY2024 · Dec 31, 2024Capital Expenditures
-624.17MCNYFY2024 · Dec 31, 2024Purchase of Investments
-3.36BCNYFY2024 · Dec 31, 2024Sale of Investments
2.46BCNYFY2024 · Dec 31, 2024Net Investing Cash Flow
-1.53BCNYFY2024 · Dec 31, 2024Long-term Debt Issuance
119.30MCNYFY2024 · Dec 31, 2024Long-term Debt Payments
-39.84MCNYFY2024 · Dec 31, 2024Common Dividends Paid
-546.04MCNYFY2024 · Dec 31, 2024Other Financing Charges
588.42MCNYFY2024 · Dec 31, 2024Net Financing Cash Flow
121.84MCNYFY2024 · Dec 31, 2024Shares Outstanding
1.11BSharesUpdated Aug 19, 2026Float Shares
445.10MSharesUpdated Aug 19, 2026% Held by Insiders
61.52%vs all stocks
% Held by Institutions
12.90%vs all stocks
Total Cash (MRQ)
1.83BCNY270.84M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.64CNYUpdated Aug 19, 2026Total Debt (MRQ)
240.21MCNY35.62M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0259xCurrent Ratio (MRQ)
2.34xBook Value per Share (MRQ)
8.21CNYUpdated Aug 19, 2026Total Assets
10.47BCNY1.55B · vs all stocks (USD)
Total Current Assets
4.02BCNYFY2024 · Dec 31, 2024Total Liabilities
1.71BCNYFY2024 · Dec 31, 2024Total Non-current Assets
6.44BCNYFY2024 · Dec 31, 2024Total Non-current Liabilities
600.32MCNYFY2024 · Dec 31, 2024Total Current Liabilities
1.11BCNYFY2024 · Dec 31, 2024Cash
1.10BCNYFY2024 · Dec 31, 2024Cash Equivalents
3.55MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents
1.13BCNYFY2024 · Dec 31, 2024Other Short-term Investments
733.86MCNYFY2024 · Dec 31, 2024Accounts Receivable
516.75MCNYFY2024 · Dec 31, 2024Inventory
506.76MCNYFY2024 · Dec 31, 2024Accounts Payable
126.09MCNYFY2024 · Dec 31, 2024Short-term Debt
129.70MCNYFY2024 · Dec 31, 2024Other Current Liabilities
13.50MCNYFY2024 · Dec 31, 2024Long-term Debt
4.18MCNYFY2024 · Dec 31, 2024Other Non-current Liabilities
433.14MCNYFY2024 · Dec 31, 2024Common Stock (Book)
1.11BCNYFY2024 · Dec 31, 2024Retained Earnings
5.09BCNYFY2024 · Dec 31, 2024Total Shareholders' Equity
8.75BCNY1.30B · vs all stocks (USD)
52-Week Low
29.25CNYUpdated Aug 19, 202652-Week High
70.99CNYUpdated Aug 19, 202652-Week Change
-31.75%vs all stocks
Beta
-0.2470xvs all stocks
50-Day MA
34.17CNYUpdated Aug 19, 2026200-Day MA
47.86CNYUpdated Aug 19, 2026Avg 10-Day Volume
29.64MSharesUpdated Aug 19, 2026Avg 30-Day Volume
34.99MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.6000CNYUpdated Aug 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $5.75B, above the global median of $1.15BNotable
Market cap (USD): 5,750,083,220.602Global Median: 1,146,734,693.424
Revenue is $670.15M, above the global median of $520.53MNotable
Revenue (USD): 670,152,143.923Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Dianthus Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Junshi Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Amneal Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Oruka Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
APT Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Jiangxi Lianchuang Optoelectronic Technology Co., Ltd.
2 interpretationsMinimal Tax and Interest DragUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Changzheng Engineering Co., Ltd.
2 interpretationsMinimal Tax and Interest DragUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Jing-Jin Electric Technologies Co. Ltd.
2 interpretationsMinimal Tax and Interest DragUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated